Skip to main content
SpringerLink
Log in

CHMP cautions developers of PEGylated drugs for children

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. EMA.CHMP Safety Working Party’s response to the PDCO regarding the use of PEGylated drug products in the paediatric population. Internet Document: [3 pages], 16 Nov 2012. Available from: URL: http://www.ema.europa.eu

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

CHMP cautions developers of PEGylated drugs for children. React. Wkly. 1430, 3 (2012). https://doi.org/10.2165/00128415-201214300-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201214300-00009

Keywords

Search

Navigation